In conclusion, our work suggests that administration of HE modulates the activity of NF-κB in a model of PD; therefore, HE may be a potent anti-PD drug that can reduce neuroinflammation, neurodegeneration, and α-synucleinopathy. The gene discussed is NFKB1; the disease is synucleinopathy.